SCHEMBL5299235

SCHEMBL5299235

O=C1C=CC(=O)c2c1ccc(O)c2O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.58
AURKA O14965 3/20 0.58
AURKB Q96GD4 2/20 0.58
CYP1A2 P05177 2/20 0.58
CYP1A1 P04798 1/20 0.58
TXNRD1 Q16881 1/20 0.58
TXNRD3 Q86VQ6 1/20 0.58
COPS5 Q92905 1/20 0.58
TXNRD2 Q9NNW7 1/20 0.58
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
ALDH1A1 P00352 5/20 0.57
HPGD P15428 5/20 0.57
MAPK1 P28482 5/20 0.57
MAPT P10636 5/20 0.57
CYP3A4 P08684 4/20 0.57
ALOX15 P16050 4/20 0.57
HSD17B10 Q99714 4/20 0.57
USP2 O75604 4/20 0.57
TP53 P04637 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695845 1.00 CDC25B (0.58) CDC25BAURKAAURKBCYP1A2CYP1A1
SCHEMBL8376967 0.78 ELANE (0.52) CDC25BAURKAAURKBCYP1A2CYP1A1
SCHEMBL11214361 0.75 MEN1 (0.46) CDC25BAURKAAURKBCYP1A2CYP1A1
Naphthazalin SCHEMBL29353283 0.75 TXNRD1 (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1
Naphthazalin SCHEMBL149279 0.75 TXNRD1 (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1
Naphthazalin SCHEMBL27700955 0.75 TXNRD1 (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1
SCHEMBL2772226 0.73 MAPT (0.86) CDC25BAURKAAURKBCYP1A2CYP1A1
Juglone SCHEMBL34185 0.73 MAPT (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1
Juglone SCHEMBL9280529 0.73 MAPT (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1
Juglone SCHEMBL29500185 0.73 MAPT (1.00) CDC25BAURKAAURKBCYP1A2CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
CN-107847466-B Formulations and methods for modulating wound healing 贝欧曼蒂克丝公司 2024-02-06 CN disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US disclosed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US disclosed
US-9938308-B2 Coordination compounds having redox non-innocent ligands and flow batteries containing the same LOCKHEED MARTIN ENERGY, LLC (US) 2018-04-10 US disclosed
CN-107847466-A For adjusting the formulation and method of wound healing 贝欧曼蒂克丝公司 2018-03-27 CN disclosed
EP-3280402-A2 FORMULATION AND PROCESS FOR MODULATING WOUND HEALING Biomendics LLC (US) 2018-02-14 EP disclosed
US-20170291916-A1 COORDINATION COMPOUNDS HAVING REDOX NON-INNOCENT LIGANDS AND FLOW BATTERIES CONTAINING THE SAME LOCKHEED MARTIN ENERGY, LLC 2017-10-12 US disclosed
WO-2017176296-A1 COORDINATION COMPOUNDS HAVING REDOX NON-INNOCENT LIGANDS AND FLOW BATTERIES CONTAINING THE SAME LOCKHEED MARTIN ADVANCED ENERGY STORAGE, LLC (US) 2017-10-12 WO disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
WO-2016164531-A2 FORMULATION AND PROCESS FOR MODULATING WOUND HEALING BioMendics, LLC (US) 2016-10-13 WO disclosed
WO-2007022979-A2 MEDIATOR SYSTEMS FOR THE ELECTROCHEMICAL REDUCTION OF ORGANIC COMPOUNDS IN AN AQUEOUS SOLUTION DYSTAR TEXTILFARBEN GMBH & CO. DEUTSCHLAND KG (DE) 2007-03-01 WO disclosed
EP-0320227-B1 Method of preventing polymer-scale formation SHINETSU CHEMICAL CO (JP) 1994-09-07 EP disclosed
US-4933399-A COATING INSIDE OF VESSEL WITH A CATIONIC DYE, DRYING, COATING WITH AN ANIONIC OR AMPHOTERIC POLYMER OR A HYDROXYL-CONTAINING COMPOUND IN A SOLVENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1990-06-12 US disclosed
US-4895575-A HAIR DYES L'OREAL (FR) 1990-01-23 US disclosed
EP-0320227-A2 Method of preventing polymer-scale formation Shin-Etsu Chemical Co., Ltd. (JP) 1989-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB CDC25B 174/4885AURKA 1543/4885AURKB 866/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB CDC25B 163/4885AURKA 1766/4885AURKB 1048/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 CDC25B 263/4885AURKA 1468/4885AURKB 972/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB CDC25B 174/4885AURKA 1543/4885AURKB 866/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB CDC25B 174/4885AURKA 1543/4885AURKB 866/4885
US-20170291916-A1 COORDINATION COMPOUNDS HAVING REDOX NON-INNOCENT LIGANDS AND FLOW BATTERIES CONTAINING THE SAME NQO1, VDAC1, SQOR CDC25B 539/4885AURKA 297/4885AURKB 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.